Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 5/20 | 0.47 |
| ▸ | TDP2 | O95551 | 10/20 | 0.43 |
| ▸ | CMA1 | P23946 | 2/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | CASP7 | P55210 | 1/20 | 0.37 |
| ▸ | CASP9 | P55211 | 1/20 | 0.37 |
| ▸ | CASP6 | P55212 | 1/20 | 0.37 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.37 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30062471 | 0.82 | SRD5A1 (0.41) | KMT2A | |
| SCHEMBL223361 | 0.81 | AHR (0.58) | AHRTDP2CMA1PDK2EIF2AK2 | |
| SCHEMBL31116942 | 0.81 | AHR (0.53) | AHRTDP2CMA1PDK2EIF2AK2 | |
| SCHEMBL19629850 | 0.81 | AHR (0.44) | AHRTDP2CMA1PDK2EIF2AK2 | |
| SCHEMBL25248436 | 0.81 | AHR (0.44) | AHRTDP2CMA1PDK2EIF2AK2 | |
| SCHEMBL18289475 | 0.80 | AHR (0.59) | AHRTDP2CMA1PDK2EIF2AK2 | |
| SCHEMBL261018 | 0.76 | AHR (0.61) | AHRTDP2PDK2CASP3CASP7 | |
| SCHEMBL30536606 | 0.72 | AHR (0.36) | AHRTDP2CMA1PDK2EIF2AK2 | |
| SCHEMBL25197491 | 0.71 | AHR (0.36) | AHRTDP2CMA1PDK2 | |
| SCHEMBL31708271 | 0.70 | AHR (0.36) | AHRTDP2GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024175114-A1 | BORON CONTAINING COMPOUNDS AND THERAPEUTIC USES THEREOF | Shanghai Yuyao Biotech Ltd. (CN) | 2024-08-29 | — | — | WO | disclosed |
| US-20240150287-A1 | N-(BENZOYL)-PHENYLALANINE COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | HANGZHOU APELOA MEDICINE RESEARCH INSTITUTE CO., LTD. (CN) | 2024-05-09 | — | — | US | disclosed |
| EP-4282865-A1 | N-(BENZOYL)-PHENYLALANINE COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | Hangzhou Apeloa Medicine Research Institute Co., Ltd. (CN) | 2023-11-29 | — | — | EP | disclosed |
| EP-4282865-A1 | N-(BENZOYL)-PHENYLALANINE COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | Hangzhou Apeloa Medicine Research Institute Co., Ltd. (CN) | 2023-11-29 | — | — | EP | disclosed |
| CN-116997550-A | N- (benzoyl) -phenylalanine compounds, pharmaceutical compositions containing same and application thereof | 杭州普洛药物研究院有限公司 | 2023-11-03 | — | — | CN | disclosed |
| CN-114853659-A | N- (benzoyl) -phenylalanine compounds, pharmaceutical compositions containing same, and uses thereof | 普洛药业股份有限公司 | 2022-08-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150287-A1 | N-(BENZOYL)-PHENYLALANINE COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | ITGB7, ITGB4, ITGA4 | AHR 1172/4885TDP2 3861/4885CMA1 1058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.